Dr Hope Rugo speaks to ecancer about key upcoming breast cancer data from ASCO 2026, focusing on how emerging therapies and biomarkers may shape future treatment strategies.

She reviews exploratory findings on TROP2 overexpression as a potential predictor of outcomes in early triple-negative breast cancer, alongside important updates from the evERA trial evaluating giredestrant plus everolimus after CDK4/6 inhibitor therapy.

The conversation also covers subgroup data from the ASCENT-07 study of sacituzumab govitecan in hormone receptor positive, HER2-negative metastatic breast cancer, as well as results from the VIKTORIA-1 trial investigating gedatolisib-based combinations in PIK3CA-mutant disease.

Finally, Dr Rugo discusses first-line treatment advances from the phase III persevERA study, comparing giredestrant plus palbociclib with standard endocrine therapy combinations.

Together, these studies reflect a rapidly evolving landscape in breast cancer, with a strong focus on targeted therapies, biomarker-driven care, and improving outcomes for patients across disease settings.